A virtual fireside chat at the 2022 Oncology Investor Conference may seem an unusual setting for mission-critical clinical updates, but not for TG Therapeutics (Nasdaq: TGTX) chief executive Michael Weiss.
In an apparently hastily-prepared filing with the US Securities and Exchange Commission (SEC), TG confirmed its boss had let slip news that the US FDA has placed a partial clinical hold on its UNITY-CLL trial.
The study is evaluating the investigational combination therapy Ukoniq (umbralisib/ublituximab) in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze